

**Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab)  
Recombinant Antibody  
Catalog # APR10100****Specification**

---

**Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P06731</a>
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.48 KDa

**Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) - Additional Information****Target/Specificity**  
CEACAM5 / CEA / CD66e**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) - Protein Information****Name** CEACAM5**Synonyms** CEA**Function**  
Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression (PubMed: [10864933](http://www.uniprot.org/citations/10864933), PubMed: [10910050](http://www.uniprot.org/citations/10910050), PubMed: [2803308](http://www.uniprot.org/citations/2803308)). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6 (PubMed:

<http://www.uniprot.org/citations/2803308> target="\_blank">2803308</a>). Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells (PubMed:<a href="http://www.uniprot.org/citations/10910050" target="\_blank">10910050</a>).

#### Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor. Apical cell membrane. Cell surface Note=Localized to the apical glycocalyx surface

#### Tissue Location


Expressed in columnar epithelial and goblet cells of the colon (at protein level) (PubMed:10436421). Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.

### Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) - Images



Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab) is more than 98.53% ,determined by SEC-HPLC.



Immobilized human CEACAM5 His Biotin at 2 µg/mL can bind Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab)  $EC_{50}=0.009815$  µg/mL